We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 10, 2022

Longitudinal Humoral Response After SARS-CoV-2 Vaccination in Ocrelizumab-Treated MS Patients

Multiple Sclerosis and Related Disorders


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis and Related Disorders
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
Mult Scler Relat Disord 2021 Nov 23;57(xx)103416, ZLE van Kempen, L Wieske, EW Stalman, LYL Kummer, PJ van Dam, AG Volkers, L Boekel, AA Toorop, EMM Strijbis, SW Tas, GJ Wolbink, M Löwenberg, C van Sandt, A Ten Brinke, NJM Verstegen, M Steenhuis, TW Kuijpers, SM van Ham, T Rispens, F Eftimov, J Killestein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading